Fri Sep 20 12:30:25 UTC 2024: ## Hedge Funds Bullish on CareDx as Institutional Investors Increase Stakes

**New York, NY – September 20th, 2024** – CareDx, Inc (NASDAQ:CDNA), a leading provider of diagnostic solutions for transplant patients, has seen a surge in interest from institutional investors and hedge funds. Renaissance Technologies LLC, a renowned quantitative investment firm, boosted its stake in CareDx by 6.2% during the second quarter, adding 88,100 shares to its portfolio, which now holds 1,512,700 shares worth $23,492,000.

This increased investment follows a trend of other institutional investors also increasing their holdings in CareDx. Caxton Associates LP, Mirae Asset Global Investments Co. Ltd., Vanguard Group Inc., and Russell Investments Group Ltd. all significantly boosted their stakes in the first quarter. Additionally, Bamco Inc. NY acquired a new position in CareDx, demonstrating growing confidence in the company’s future.

Despite this positive trend, CareDx’s stock opened at $29.88 on Friday, a far cry from its 12-month high of $34.84. However, analysts remain optimistic about the company’s potential. BTIG Research upgraded CareDx to a “buy” rating and set a $40.00 price target, while Craig Hallum also issued a “buy” rating and raised its price target to $32.00. However, Wells Fargo & Company initiated coverage with an “underweight” rating and a $28.00 price target.

While several analysts are bullish, insider transactions have cast some shadow on the company. Alexander L. Johnson, an insider at CareDx, has sold a significant number of shares in recent months. This insider selling activity could be interpreted as a sign of bearish sentiment, although the reasons behind these sales remain unclear.

Overall, despite insider selling, CareDx continues to attract significant institutional investment, indicating a strong belief in the company’s long-term prospects. With its innovative diagnostic solutions for transplant patients and a growing market, CareDx remains a company to watch closely.

Read More